

Horizon CHOsource platform

written by CAP TODAY

May 19, 2020

May 2020—Horizon Discovery Group announced its cGMP-compliant CHOsource platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon's Chinese hamster ovary cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, the company reported in a press statement, enabling Immutep and Batavia Biosciences to reach a milestone in the preclinical development of the compound.

Horizon's gene-edited glutamine synthetase knockout CHO K1 cell line expression system, offered by Batavia Biosciences as part of its STEP-mAb service, was used to generate a high yielding cell line for Immutep's IMP761 product candidate, an agonist antibody targeting the immune checkpoint lymphocyte-activation gene 3.

The CHOsource biomanufacturing platform aims to help companies move from the DNA sequence of their potential biotherapeutic to clinical manufacturing.

[Horizon Discovery](#), 303-604-9499



©2026 CAP TODAY, all rights reserved.